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is 3.61% worldwide, and the infection rate is higher in the African 
(8.83%) and Western Pacic (5.26%) regions [1]. The prevalence in 
South Korea was estimated to be about 3%, according to the Ko-
rea National Health and Nutrition Examination Survey (KNHANES) 
in the year 2016, indicating that our mode of transmission is shift-
ing from perinatal transmission to horizontal transmission [2]. To 
properly manage the infection, the Asian Pacic Association for 
the Study of the Liver (APASL) proposed a guideline stating that 
HBV DNA titer plays a crucial role in the staging and monitoring 
of the disease as well as in choosing a treatment strategy [3]. 
HCV, unlike HBV, cannot be prevented by vaccination, and it 
has been only a few years since an effective treatment regimen 
was developed. The prevalence of HCV infection is 2.8% world-
wide [4] and 0.78% in Korea, increasing with age [5]. The Ameri-
can Association for the Study of Liver Diseases (AASLD) and the 
Infectious Diseases Society of America (IDSA) presented a guide-
line on how to best manage HCV infection. According to this guide-
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Background: Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections remain a serious health problem despite advancements in their pre-
vention and treatment. Guidelines on their management recommend using viral DNA/RNA titers. Thus, accurate measurement and prompt report-
ing are crucial.
Methods: The performances of the Aptima HBV and HCV Quant assays (Hologic Inc., USA) were analyzed. The results were compared with those 
of Cobas 4800 (Roche Molecular Systems, USA). Linearity, limit of detection (LoD), and precision were evaluated as recommended in each corre-
sponding CLSI guideline. 
Results: Passing-Bablok regression analysis showed a high correlation between the two assays: regression line was y =0.0684+1.025x (95% 
CI: 0.9604-1.092) for HBV and y = -0.9650+1.141x (95% CI: 1.071-1.226) for HCV. Agreement between the assays’ qualitative results based on 
categorical analysis was 82.30% (185/224) (κ: 0.738, 95% CI: 0.701-0.775) for HBV and 94.52% (69/73) (κ: 0.855, 95% CI: 0.796-0.914) for 
HCV. The LoD values for HBV and HCV were 4.448 IU/mL and 6.166 IU/mL, respectively. The percent coefficient of variation (%CV) for the HBV as-
say for both low and high positive controls was less than 2%, whereas for the HCV assay, %CV for low positive control was 3.20%. 
Conclusions: Overall, the Aptima HBV and HCV Quant assays demonstrated a high correlation with Cobas 4800. These tests were both sensitive 
and precise. Therefore, we conclude that the Aptima assay is a practical tool in the management of HBV- and HCV-infected patients.
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line, HCV RNA titer measurement is needed to make a diagnosis, 
monitor treatment efcacy, and test for reinfection [6]. Thus, accu-
rate measurement of HBV DNA and HCV RNA titers is crucial for 
the proper management of HBV and HCV infections.
Instruments measuring viral genetic material mostly use a real-
time, quantitative polymerase chain reaction (PCR) method whereas 
the Aptima assay (Hologic Inc., San Diego, CA, USA) uses tran-
scription-mediated amplication (TMA) [7]. In addition, the plat-
form that the Aptima assay utilizes, the Panther system, offers a 
fully-automated random access system, allowing prompter results 
and less hands-on time for clinical pathologists carrying out the 
task [8].
In this paper, Aptima HBV and HCV assays’ linearity, limit of 
detection (LoD), precision, and correlation with Cobas 4800 (Roche 
Molecular Systems, Pleasanton, CA, USA) were evaluated to as-
sess the analytical performance of these assays.
MATERIALS AND METHODS
1. Clinical specimens
For the comparison study, residual plasma samples that had 
been tested with Cobas 4800 for either HBV or HCV genetic ma-
terial were used; 224 HBV residual samples and 73 HCV residual 
samples were collected. They had been stored at -80°C for 9 months, 
at most.
2. Aptima HBV and HCV Quant assays
The viral genetic load was measured using Aptima HBV and 
HCV Quant assays. The Aptima HBV Quant assay uses real-time 
TMA technology to quantify HBV DNA. It targets two highly-con-
served regions in the virus’s polymerase and surface genes to in-
crease the assay’s tolerance for potential mutations. These targets 
are captured using capture oligonucleotides coupled to magnetic 
beads, which can be separated from the specimen in a magnetic 
eld. Once the target is amplied, uorescently-labeled probes 
(torches) are used for detection. The time taken for the uorescent 
signal to reach a specied threshold is inversely proportional to 
the starting HBV concentration. The concentration of a sample is 
determined automatically by the Panther system software. The 
procedure for the HCV assay is almost identical to that of HBV. 
The Aptima HCV assay targets two highly-conserved regions at 
the relatively large 5’UTR of the HCV genome.
3. Precision, Linearity, and LoD
Precision was assessed using 3 different target concentrations 
or 3 control samples (negative, low positive, and high positive 
controls) that were included in each assay. Linearity was conrmed 
using 7 concentrations provided in the AcroMetrix HBV, HCV Panel 
1.2 mL (Thermosher Scientic) [9]. Among these, the ones with 
the lowest HBV DNA and HCV RNA concentrations (50 IU/mL) 
were used for serial dilution to estimate the LoD. Five concentra-
tions were made and measured 20 times each using the Aptima 
assay [10].
4. Statistical analysis
For statistical analysis, Microsoft Excel 2013 (Microsoft, Seattle, 
WA, USA), Analyze-it for Microsoft Excel Method Evaluation Edi-
tion version 5.40.2 (Analyse-it Software, Ltd., City West Business 
Park, Leeds, UK), IBM SPSS Statistics v.23 (IBM Corp., North Cas-
tle, NY, USA), and Prism 8.0 (GraphPad Software, Inc., La Jolla, 
CA, USA) were used. Passing-Bablok regression, Bland-Altman 
analysis, and Cohen’s kappa coefcient were used to evaluate the 
correlation between Cobas 4800 and Aptima. Linearity was evalu-





Of the 224 samples collected, only 84 were quantied in both 
assays. The results were compared using Passing-Bablok regres-
sion and Bland-Altman analysis. Passing-Bablok regression analy-
sis demonstrated a high correlation between the two data sets, 
with a regression line slope of 1.025 (95% CI: 0.9604-1.092) and a 
correlation coefcient r of 0.979 (Fig. 1). Average bias between 
them was -0.19 Log IU/mL (SD=0.34 IU/mL) (Cobas 4800–Ap-
tima), with no specic trend as the HBV titer increased. Aptima 
quantied more than two standard deviations higher than Cobas 
4800 for two samples, and more than three standard deviations 
higher for one sample (Fig. 2). Categorical distribution of each sam-
ple is summarized in Table 1. The lower limit of quantication 
(LLOQ) was 10 IU/mL for both Cobas 4800 and Aptima. Agree-
ment between the assays’ qualitative results was 82.30% (185/224) 
(κ: 0.738, 95% CI: 0.701-0.775).
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2) HCV
Of the 73 samples collected, only 48 were quantied in both 
assays. The results were compared using Passing-Bablok regres-
sion and Bland-Altman analysis. Passing-Bablok regression analy-
sis demonstrated a regression line slope of 1.141 (95% CI: 1.071-
1.226), with a correlation coefcient r of 0.944 (Fig. 3). Average 
bias between them was 0.19 Log IU/mL (SD=0.40 IU/mL) (Cobas 
4800–Aptima), with no specic trend as the HCV titer increased. 
For four samples, Aptima quantied more than two standard de-
viations lower than Cobas 4800 (Fig. 4). Categorical distribution of 
each sample is summarized in Table 1. The LLOQ was 15 IU/mL 
for Cobas 4800 and 10 IU/mL for Aptima. Agreement between the 
assays’ qualitative results was 94.52% (69/73) (κ: 0.855, 95% CI: 0.796-
0.914).
2. Linearity
To validate the linearity of both Aptima HBV and HCV assays, 2 
replicates of 7 points from the AcroMetrix HBV, HCV Panel 1.2 mL 
were tested. The average value of the 2 replicates of the 7 points 
are plotted in Figs. 5 and 6. The determination coefcient values 
of the Aptima HBV and HCV assays were 0.9971 and 0.9935, re-
spectively (Figs. 5, 6).
Table 1. Classification of HBV and HCV samples according to results 
obtained by Cobas 4800 and Aptima
HBV
Cobas 4800
Not detected Pos. <LLOQ Quantified
Aptima Not detected 59 6 -
Pos. <LLOQ 27 42 4
Quantified - 2 84
HCV
Cobas 4800
Not detected Pos. <LLOQ Quantified
Aptima Not detected 20 2 -
Pos. <LLOQ - 1 2
Quantified - - 48
Abbreviations: LLOQ, lower limit of quantification; Pos. <LLOQ, Detected but be-
low the lower limit of quantification.
Fig. 2. Bland-Altman analysis of 84 HBV samples that quantified with-
in the linear measuring range of both tests. The average bias (−0.19 
Log IU/mL; SD=0.34 IU/mL) and the 95% confidence interval of the 
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Fig. 1. Passing-Bablok regression on 84 HBV samples quantified within 
the linear measuring range of both the Cobas 4800 and Aptima assays. 















Cobas 4800 (Log IU/mL)
 2 4 6 8 10
y=0.0684+1.025x
Fig. 3. Passing-Bablok regression on 48 HCV samples quantified within 
the linear measuring range of both the Cobas 4800 and Aptima as-
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3. LoD
To estimate the LoD, serial dilution using a sample from the Ac-
roMetrix HBV Panel 1.2 mL and the AcroMetrix HCV Panel 1.2 mL 
was done. Five concentrations were made and measured 20 times 
each for both HBV and HCV. LoD values obtained by probit anal-
ysis were 4.448 (95% CI: 3.512-8.238) for HBV and 6.166 (95% CI: 
4.711-11.38) for HCV.
4. Precision
To evaluate the precision of the Aptima HBV and HCV assay, 
the percent coefcient of variation (%CV) was calculated by mea-
suring the concentration of 3 control samples (negative, low posi-
tive, and high positive controls) twice each day for 10 days. 
1) HBV
Runs using negative control always resulted in no detection, so 
%CV could not be calculated. The %CV for low positive control 
(2.88 Log IU/mL; SD=0.05) was 1.66%, and for high positive con-
trol (4.52 Log IU/mL; SD=0.04), it was 0.95%.
2) HCV
Runs using negative control always resulted in no detection, so 
%CV could not be calculated. The %CV for low positive control 
(2.26 Log IU/mL; SD=0.07) was 3.20%, and for high positive con-
trol (5.44 Log IU/mL; SD=0.09), it was 1.69%.
DISCUSSION
In this study, we evaluated the analytical performances of the 
Aptima HBV and HCV Quant assays by comparing them to those 
of Cobas 4800. A close correlation between the two assays was 
found; Bland-Altman analysis showed an average quantication 
bias (Cobas 4800–Aptima) of only -0.19 Log IU/mL for HBV and 
+0.19 Log IU/mL for HCV. This average difference is almost iden-
tical to what was presented in a prior study that compared the 
Aptima HBV assay with the COBAS Ampliprep/COBAS TaqMan 
HBV DNA Test v2.0 (Roche) [11]. Their average difference (Ap-
tima–CA PCTMv2) was -0.195 Log IU/mL [11]. In another article 
comparing Aptima HCV assay with the COBAS Ampliprep/CO-
BAS TaqMan HCV RNA Test v2.0, the average difference (Ap-
tima–Abbott) was 0.11, which was similar to the average differ-
ence obtained in our study [12]. According to the categorical dis-
tribution of each sample shown in Table 1, 27 out of the 86 HBV 
samples that Cobas 4800 reported as “Not detected” were posi-
tive but below the LLOQ according to the Aptima assay. In con-
trast, only 6 of the 65 samples that Aptima reported as “Not de-
tected” were reported as positive but below the LLOQ by Cobas 
Fig. 4. Bland-Altman analysis of 48 HCV samples that quantified 
within the linear measuring range of both tests. The average bias (0.19 
Log IU/mL; SD=0.40 IU/mL) and the 95% confidence interval of the 
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4800. The four samples that were below the LLOQ in the Aptima 
assay but quantied in Cobas 4800 had very low concentrations, 
ranging from 11.1 IU/mL to 25.4 IU/mL. The two samples that 
were below the LLOQ in the Cobas 4800 assay but quantied in 
Aptima had very low concentrations as well. Their exact num-
bers were 10.0 IU/mL and 12.6 IU/mL. The qualitative results of 
the two assays showed substantial agreement, with a Cohen’s co-
efcient κ of 0.738 for HBV and 0.855 for HCV. The Aptima HBV 
assay quantied more than two standard deviations higher than 
Cobas 4800 for two samples and more than three standard devia-
tions higher for one sample (Fig. 2). In the case of HCV, Aptima 
quantied more than two standard deviations lower than Cobas 
4800 for four samples (Fig. 4). Prior studies have demonstrated 
that such discrepancies were statistically related to a certain geno-
type of the virus, although its clinical signicance was less clear 
[11]. Genotyping of the discrepant samples in our study could not 
be done due to a lack of remnant samples.
The LoD values for HBV and HCV were 4.448 IU/mL and 6.166 
IU/mL, respectively. In the case of HBV, the estimated value was 
in accordance with the LoD stated on the package insert paper 
[12,13]. In contrast, the LoD of the HCV assay differed from that 
stated on the package insert paper. It was 3.9 IU/mL for plasma [14], 
which was even lower than the lower LoD range of 95% CI ob-
tained in our study. However, when compared to the LoD of the 
Cobas 4800 HCV assay, which was 9.2 IU/mL (95% CI: 7.8-11.5 IU/
mL), the LoD obtained in our study was lower, albeit with an 
overlapping 95% CI [15].
The Aptima HBV and HCV assays were both found to be pre-
cise. The %CV of the HBV assay for low positive control was 1.66%, 
and for high positive control, it was 0.95%. While these were both 
less than 2%, the %CV of HCV for low positive control was 3.20%, 
and for high positive control, it was 1.69%. In spite of the fact that 
the %CV of HCV for low positive control exceeded 3%, this value 
was similar to what prior studies obtained at low concentrations 
with the Aptima HCV assay [12], and it is better when compared 
to studies that used other HCV assays [16].
Even though the analytical performance of the Aptima assays 
was evaluated as satisfactory, our study had some limitations. Re-
garding samples that showed a discrepancy between Cobas 4800 
and Aptima assays, genotyping of the viruses could not be done 
due to a lack of remnant samples. In addition, the number of HCV 
samples was too few, and the samples were mostly high-titered. If 
we had collected more positive samples in the lower range, we 
might have gotten better results. As for the difference between 
the measured LoD and the LoD stated in the insert paper for HCV, 
if we had measured each concentration more, our estimation might 
have been closer to the stated LoD, and the 95% CI would have 
been narrower as well.
Despite these limitations, we found the results of the Aptima 
assay to be highly correlated to that of Cobas 4800. Moreover, ac-
cording to the other parameters that we evaluated, Aptima was 
both sensitive and precise. Therefore, we conclude that the Ap-
tima assay is a practical tool in the diagnosis and management of 
HBV- and HCV-infected patients.
요 약
배경: 간염을 일으키는 HBV 및 HCV 감염은 치료 및 예방법의 발
전에도 불구하고 여전히 심각한 보건 문제이다. HBV 및 HCV 감염
에 대한 가이드라인들은 바이러스의 핵산물질 양을 측정하여 감
염의 진단 및 치료효과 모니터링에 사용할 것을 권장하고 있다. 그
렇기에 신속하고 정확한 핵산물질 측정이 매우 중요하다.
방법: 이 논문에서는 Aptima HBV 및 HCV Quant assay (Hologic 
Inc., USA)의 성능을 Cobas 4800 (Roche Molecular Systems, USA)
와 비교하여 평가하였다. 또한 직선성, 정밀도, 그리고 최소검출농
도는 해당하는 CLSI 가이드라인에 따라 평가하였다.
결과: 회귀분석 결과 두 분석 방법 간에 높은 상관성을 보였다. 
HBV의 회귀식은 y=0.0684+1.025x (95% CI: 0.9604-1.092), HCV의 
회귀식은 y= -0.9650+1.141x (95% CI: 1.071-1.226)이었다. 두 assay 
간의 일치도는 HBV의 경우 82.30% (185/224) (κ: 0.738, 95% CI: 
0.701-0.775), HCV의 경우 94.52% (69/73) (κ: 0.855, 95% CI: 0.796-
0.914)였다. HBV 및 HCV의 최소검출농도는 각각 4.448 IU/mL 및 
6.166 IU/mL이었다. 변이계수는 HBV에서 낮은 농도 및 높은 농도 
모두 2% 미만으로 측정된 반면 HCV의 경우 낮은 농도 검체에서 
3.20%로 측정되었다. 
결론: Aptima HBV 및 HCV Quant assay는 Cobas 4800과 높은 상
관관계를 보였으며, 민감하고 정밀한 검사 방법으로 사료되었다. 
그러므로 Aptima assay는 HBV 및 HCV 환자의 관리에 실용적인 
기여를 할 수 있을 것으로 기대된다.
Conflicts of Interest
None declared.
최유정 외: Performance of Aptima HBV, HCV Quant Assays
https://doi.org/10.47429/lmo.2021.11.3.177182   www.labmedonline.org
REFERENCES
1. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of 
worldwide prevalence of chronic hepatitis B virus infection: a system-
atic review of data published between 1965 and 2013. Lancet 2015;386: 
1546-55. 
2. Yim SY and Kim JH. The epidemiology of hepatitis B virus infection 
in Korea. Korean J Intern Med 2019;34:945-53. 
3. Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-
Pacic clinical practice guidelines on the management of hepatitis B: a 
2015 update. Hepatol Int 2016;10:1-98.
4. Petruzziello A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C. 
Global epidemiology of hepatitis C virus infection: An up-date of the 
distribution and circulation of hepatitis C virus genotypes. World J 
Gastroenterol 2016;22:7824-40. 
5. Jeong SH, Jang ES, Choi HY, Kim KA, Chung W, Ki M. Current status 
of hepatitis C virus infection and countermeasures in South Korea. Ep-
idemiol Health 2017;39:e2017017.
6. Chung RT, Ghany MG, Kim AY, Marks KM, Naggie S, Vargas HE, et al. 
Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations 
for Testing, Managing, and Treating Hepatitis C Virus Infection. Clin 
Infect Dis 2018;67:1477-92. 
7. Aretzweiler G, Leuchter S, Simon CO, Marins E, Frontzek A. Generat-
ing timely molecular diagnostic test results: workow comparison of 
the cobas® 6800/8800 to Panther. Expert Rev Mol Diagn 2019;19:951-7. 
8. May S, Adamska E, Tang JW. Evaluating the aptima HIV-1 quant Dx, 
HCV quant Dx and HBV quant assays against the Abbott HIV-1, HCV 
and HBV RealTime assays. J Clin Virol 2018;106:7-10.
9. Clinical and Laboratory Standards Institute. Evaluation of the linearity 
of quantitative measurement procedures. 2nd ed. CLSI guideline EP06. 
Wayne, PA: Clinical and Laboratory Standards Institute, 2020. 
10. Clinical and Laboratory Standards Institute. Evaluation of detection ca-
pability for clinical laboratory measurement procedures; Approved 
guideline. 2nd ed. CLSI guideline EP17-A2. Wayne, PA: Clinical and 
Laboratory Standards Institute, 2012. 
11. Schønning K, Johansen K, Nielsen LG, Weis N, Westh H. Analytical 
performance of the Hologic Aptima HBV Quant Assay and the CO-
BAS Ampliprep/COBAS TaqMan HBV test v2.0 for the quantication 
of HBV DNA in plasma samples. J Clin Virol 2018;104:83-8.
12. Worlock A, Blair D, Hunsicker M, Le-Nguyen T, Motta C, Nguyen C, et 
al. Analytical characteristics and comparative evaluation of Aptima 
HCV quant Dx assay with the Abbott RealTime HCV assay and Roche 
COBAS AmpliPrep/COBAS TaqMan HCV quantitative test v2.0. Virol J 
2017;14:66.
13. Hologic, Inc. Aptima HBV Quant Assay. https://www.hologic.com/
sites/default/les/2019-03/AW-15644_002_01_0.pdf (Last accessed on 
September 2020)
14. Hologic, Inc. Aptima HCV Quant Dx Assay. https://www.hologic.com/ 
sites/default/les/2019-03/AW-14498_002_01_0.pdf (Last accessed on 
September 2020)
15. Roche Diagnostics. Cobas® HCV GT for use on the cobas® 4800 Sys-
tem. https://diagnostics.roche.com/global/en/products/params/cobas-
hcv-gt-for-use-on-thecobas-4800-system.html (Last accessed on Sep-
tember 2020)
16. Braun P, Delgado R, Drago M, Fanti D, Fleury H, Gismondo MR, et al. 
European multicenter study on analytical performance of DxN veris 
system HCV assay. J Clin Microbiol 2017;55:1186-92.
 
 
